Fecal Immunochemical Test (FIT) is commonly used for colorectal cancer screening around the world. At the same time, it can be used in general practice as a test for those who have lower gastrointestinal symptoms. Patients who have non-specific symptoms, such as a change in bowel habits, weight loss, anemia and abdominal pain, are at “low but not no risk” of having colorectal cancer. In UK, the National Institute of Health and Care Excellence (NICE) recommends FIT for symptomatic patients in DG30 guidelines.
OC-SENSOR is endorsed as the cost-effective FIT to assess the risk of colorectal cancer and to guide further investigation in NICE DG30 guidelines. It is “recommended for adoption in primary care to guide referral for suspected colorectal cancer in people without rectal bleeding who have unexplained symptoms but do not meet the criteria for a suspected cancer pathway referral outlined in NICE's guideline on suspected cancer (recommendations 1.3.1 to 1.3.3).”
Following a successful service evaluation Nottingham University Hospital Trust began offering a symptomatic FIT service in late 2017, the earliest adopters in the UK. Click to read *external link
Norfolk and Norwich University NHS Trust went live with their symptomatic FIT service in late 2018. They describe their FIT pilot study and lessons learnt. Click to read *external link
Visit for more information: http://www.fit-screening.co.uk/services Provided by Mast Group (OC-SENSOR distributor)
Fully automated analyzer for detecting hemoglobin on stool with quantitative results.
Compact size and fully automated analyzer for detecting hemoglobin on stool with quantitative results.